Abstract:LB-367 Somatic mutations in the EGFR kinase are a cause of non-small cell lung cancer, and the presence of these mutations correlates with response to small-molecule tyrosine kinase inhibitors. Despite initial responses, longer-term efficacy of TKIs targeting the EGFR has been limited by the emergence of drug resistance, often conferred by an additional mutation of Threonine 790 in the EGFR to Methionine (T790M). This mutation, which lies in the ATP binding pocket of the kinase, confers resistance to anilinoquinazoline inhibitors including gefitinib and erlotinib. Importantly, the T790M mutant remains sensitive to a number of irreversible inhibitors, including HKI-272, Cl-387,785 and Cl-1033. These irreversible inhibitors are expected to bind in the ATP binding cleft in a manner analogous to similar reversible inhibitors, but they have an additional reactive group that forms a covalent bond with Cys 773 at the edge of the ATP binding cleft. The activity of these inhibitors against the T790M mutant therefore presents a paradox â\#8364;“ the steric effects of the T790M mutation that are presumed to underlie resistance to reversible anilinoquinazoline inhibitors should also interfere with the targeting of the irreversible inhibitors. To better understand the effects of the T790M mutant and the mechanism by which it confers resistance, we have determined the structure of this mutant alone and in complex with irreversible inhibitor HKI-272. Additionally, we have studied the kinetics and inhibitor-binding properties of the T790M mutant, the L858R/T790M double mutant, and the wild-type EGFR kinase. Surprisingly, using a direct binding assay we find that gefitinib binds to the T790M and L858R/T790M mutants with low nanomolar affinity (Kd=~5 nM), indicating that the T790M substitution does not sterically block gefitinib binding. These results are further supported by the crystal structure of HKI-272 in complex with the T790M mutant, which shows that the binding mode of HKI-272 is the same as that expected in the wild-type kinase. Kinetic analysis of the T790M mutant shows that it is approximately 5-fold more active that the wild-type kinase, with a similar Km for ATP. Interestingly, the L858R/T790M double mutant also has a Km for ATP equivalent to that of the wild-type kinase, whereas the L858R and G719S single mutants have markedly impaired affinity for ATP. Collectively, our findings indicate that much of the resistance induced by the T790M mutation may stem from its ability to restore wild-type affinity for ATP, rather than from its steric effects on inhibitor binding as was previously supposed. Since TKIs must compete with ATP to achieve their intended effect, their effective potency is diminished by the enhanced ATP-affinity. Irreversible inhibitors, as a class, overcome this effect through covalent binding.

Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.

HER2 Overexpression Reverses the Relative Resistance of EGFR-mutant H1975 Cell Line to Gefitinib.

Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells

Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells

MicroRNA-34a Overcomes HGF-mediated Gefitinib Resistance in EGFR Mutant Lung Cancer Cells Partly by Targeting MET.

Hypoxia-inducible Factor-1 Signaling Pathway Influences the Sensitivity of HCC827 Cells to Gefitinib.

Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.

EGFR kinase mutations in NSCLC: Unexpected structural and kinetic insights into the mechanism of the T790M resistance mutation and its inhibition by irreversible inhibitors including HKI-272

The T790m Mutation in Egfr Kinase Causes Drug Resistance by Increasing the Affinity for Atp

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity

Mefatinib As First-Line Treatment of EGFR Sensitizing Mutation-Positive Non-Small-cell Lung Cancer: A Phase III Efficacy and Biomarker Study.

HDGF Promotes Gefitinib Resistance by Activating the PI3K/AKT and MEK/ERK Signaling Pathways in Non-Small Cell Lung Cancer

244-Mpt Overcomes Gefitinib Resistance in Non-Small Cell Lung Cancer Cells

Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway

T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.

TGF-β1 Induces Erlotinib Resistance in Non-Small Cell Lung Cancer by Down-Regulating PTEN

Epidermal Growth Factor Receptor–Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells